drugset / Trial / NCT06175767
A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease
RandomizedSequentialDouble-blindTreatment
Summary
A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease. Primary objective of the study is to evaluate the safety and tolerability of MT101-5 400 mg and 600 mg oral tablet total daily dose compared to Placebo in subjects with Parkinson's Disease.
Timeline
- Start
- 2025-03-14
- Primary completion
- 2025-07
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MT101-5 | Unknown | 400 mg | Oral |
| Subject | MT101-5 | Unknown | 600 mg | Oral |